VAC 1

Drug Profile

VAC 1

Alternative Names: Antigen-presenting allogeneic dendritic cells - Asterias Biotherapeutics; AST-VAC1; Cancer vaccine - Argos/Geron; GRNVAC 1; hTERT RNA vaccine - Argos/Geron; RNA-loaded autologous dendritic cell vaccine - Argos/Geron; VAC1

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Argos Therapeutics Inc; Geron Corporation
  • Developer Asterias Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 04 Oct 2016 Immunomic Therapeutics in-licenses NTC’s RNA-OUT™ and HyperGro™ technology from Nature Technology Corporation
  • 27 Sep 2016 Asterias Biotherapeutics plans a confirmatory phase IIb trial for VAC 1 in 2018
  • 29 Mar 2016 Asterias Biotherapeutics has patent protection for VAC 1 in USA, Australia, Europe, Canada, China, Hong Kong, and Japan (Asterias Biotherapeutics 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top